Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20267207 | 1.00 | MEN1 (0.36) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL9796636 | 1.00 | MEN1 (0.36) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL9513620 | 0.95 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL12306831 | 0.87 | MEN1 (0.35) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL18483727 | 0.84 | MEN1 (0.34) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL14287629 | 0.83 | MEN1 (0.35) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL13316609 | 0.83 | MEN1 (0.35) | MEN1KMT2AKDM4CNPC1RAB9A | |
| SCHEMBL4192173 | 0.83 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL8217193 | 0.83 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL20631949 | 0.83 | MEN1 (0.33) | MEN1KMT2AKDM4CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110088108-B | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | 联合疗法公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-3551632-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION THERAPEUTICS AS (DK) | 2024-06-12 | — | — | EP | disclosed |
| US-20220362259-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | UNION therapeutics A/S (DK) | 2022-11-17 | — | — | US | disclosed |
| CN-109970760-B | ACC inhibitors and uses thereof | 吉利德阿波罗公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-3628320-B1 | ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2022-03-16 | — | — | EP | disclosed |
| US-11065257-B2 | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2021-07-20 | — | — | US | disclosed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | disclosed |
| US-10906915-B2 | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | LEO PHARMA A/S (DK) | 2021-02-02 | — | — | US | disclosed |
| US-20200323869-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA A/S (DK) | 2020-10-15 | — | — | US | disclosed |
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | SCHRÖDINGER, INC. | 2020-04-02 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| US-8969557-B2 | ACC inhibitors and uses thereof | Nimbus Apollo, Inc. (US) | 2015-03-03 | — | — | US | disclosed |
| EP-2776038-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| WO-2013071169-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. (US) | 2013-05-16 | — | — | US | disclosed |
| US-4892961-A | Amino acid derivatives, and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-01-09 | — | — | US | disclosed |
| EP-0210657-B1 | AMINO ACID DERIVATIVES, AND THEIR PRODUCTION | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1989-05-03 | — | — | EP | disclosed |
| EP-0210657-A1 | Amino acid derivatives, and their production | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102323-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | MEN1 4200/4885KMT2A 2071/4885KDM4C 1342/4885 |
| US-10906915-B2 | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE12 | MEN1 4067/4885KMT2A 2996/4885KDM4C 1106/4885 |
| US-20200323869-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE12 | MEN1 4067/4885KMT2A 2996/4885KDM4C 1106/4885 |
| US-20220362259-A1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | PDE4A, PDE4B, PDE12 | MEN1 4067/4885KMT2A 2996/4885KDM4C 1106/4885 |
| US-11065257-B2 | Substituted pyrazoloazepin-4-ones and their use as phosphodiesterase inhibitors | PDE4A, PDE4B, PDE12 | MEN1 4067/4885KMT2A 2996/4885KDM4C 1106/4885 |
| US-20130123231-A1 | ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | MEN1 4200/4885KMT2A 2071/4885KDM4C 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.